The MPN Research Foundation and LLS Partner for a Second Round of the Myelofibrosis Challenge

    The MPN Research Foundation and LLS Partner for a Second Round of the
                           Myelofibrosis Challenge

PR Newswire

CHICAGO and WHITE PLAINS, N.Y., Feb. 14, 2013

CHICAGOand WHITE PLAINS, N.Y., Feb. 14, 2013 /PRNewswire/ --In 2012, The
Myeloproliferative Neoplasm (MPN) Research Foundation and The Leukemia &
Lymphoma Society (LLS) jointly issued the MF Challenge Grant, seeking
innovative approaches to reversing fibrosis in patients with myelofibrosis
(MF). The challenge resulted in many high quality applications, therefore, the
two organizations are continuing with a second round of applications.

Applicants for this concept grant program will have until April 1, ^ 2013 to
submit their proposal for funding of up to $100,000 per grant. The grant
review will take place in May 2013.

"Concept grants" are used to identify innovative and novel approaches to an
issue. Since the objective is to identify and fund new approaches to fibrosis,
applicants are not required to have preliminary data. Success for a grant is
defined as proving an idea is worth pursuing further.

Fibrosis is the formation of excessive fibrous connective tissue in place of
healthy tissue. The disease myelofibrosis (one of the myeloproliferative
neoplasms) is characterized by fibrosis in the bone marrow. Though some
patients may live for many years with relatively mild symptoms, others have a
much bleaker outlook. The only potential cure for MF is a stem cell
transplant, which is an option for only a small number of MF patients. The
disease in a small proportion of MF patients can transform to acute myeloid
leukemia (AML), a highly lethal type of blood and bone marrow cancer that
progresses rapidly.

MPN Research Foundation President Barbara Van Husen says this grant program
has already stimulated scientific interest in myelofibrosis.

"It is our hope that by bringing a broad range of experts to focus on
myelofibrosis we can capitalize on important research in other areas of
fibrosis and cancer research for the benefit of MPN patients and many others,"
Van Husen said.

"LLS aggressively and proactively searches for opportunities to improve the
lives of patients by funding areas of research addressing critical unmet
medical needs. The lack of a cure for the majority of patients with
myelofibrosis presents a challenge that we must address," said Richard C.
Winneker, Ph.D., LLS senior vice president, research. "LLS looks forward to
our continued partnership with the MPN Research Foundation for a second year
to meet the challenge for patients with myelofibrosis."

About The Myeloproliferative Research Foundation
The MPN Research Foundation was started in 2000. Founded by patients, for
patients, terms on every research grant are negotiated to maximize the dollars
invested in actual research. The Foundation's esteemed Scientific Advisory
Board utilizes a rigorous selection process to ensure donations are allocated
to the most innovative research projects. To date, the Foundation has awarded
over nine million dollars for MPN research. The MPN Research Foundation has
received funding from MPN patients and from Sanofi Oncology and Incyte
Corporation to help support the MF Challenge. To learn more about the
Foundation, visit

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society^® (LLS) is the world's largest voluntary
health agency dedicated to blood cancer. The LLS mission is to cure leukemia,
lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of
patients and their families. LLS funds lifesaving blood cancer research around
the world and provides free information and support services. Founded in 1949
and headquartered in White Plains, NY, LLS has chapters throughout the United
States and Canada. To learn more, visit or contact the
Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m.
to 6 p.m. ET.

Media contact: Andrea Greif, (914) 821-8958,

SOURCE The Leukemia & Lymphoma Society

Press spacebar to pause and continue. Press esc to stop.